Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 152-155 , May 2010

Why is non−high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?

  • Allan Sniderman, MD

      Affiliations

    • Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7.22, Royal Vic Hosp, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    • Corresponding Author InformationCorresponding author.
    • ,
  • Matt McQueen, MD, PhD

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    • ,
  • John Contois, PhD

      Affiliations

    • Maine Standards Company, Windham, ME, USA
    • ,
  • Ken Williams, PhD

      Affiliations

    • KenAnCo Biostatistics and University of Texas Health Science Centre at San Antonio, TX, USA
    • ,
  • Curt D. Furberg, MD, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received 4 March 2010 ,Accepted 9 March 2010.

References 

  1. Sniderman AD, de Groot E, Couture P. ApoB and the atherogenic apoB dyslipoproteinemias. In:  Kwiterovich PO editors. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia, PA: Lippincott Williams & Wilkins; 2009;p. 196–210
  2. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988;29:1461–1473
  3. Sniderman AD, Vu H, Cianflone K. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis. 1991;89:109–116
  4. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844
  5. Di Angelantonio E, Sarwar N, Perry P, et al. The Emerging Risk Factors Collaboration J. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc. 2009;302:1993–2000
  6. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc. 2007;298:776–785
  7. Shai I, Rimm EB, Hankinson SE, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation. 2004;110:2824–2830
  8. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. J Am Med Assoc. 2005;294:326–333
  9. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. J Clin Lipidol. 2007;1:583–592
  10. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonsnce compared with standard lipids and apolipoproteins in predicting incident cardiovascualr disease in women. Circulation. 2009;119:931–939
  11. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ. Pittsburgh Epidemiology of Diabetes Complications Study. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type! diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study Diabetologia. 2003;46:674–682
  12. Sniderman AD, Williams K, McQueen MJ, Furberg CD. When is equal not equal?. J Clin Lipidol. 2010;4:83–88
  13. Sniderman AD, St-Pierre A, Cantin B, Dagenais GR, Depres J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91:1173–1177
  14. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247–258
  15. Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL lowering therapy: implications for clinical practice. J Clin Lipidol. 2008;2:38–42
  16. Sniderman AD, Tremblay A, Bergeron J, Gagne C, Couture P. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol. 2007;1:256–263
  17. de Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Endocrinol Metab. 2008;4:608–618

PII: S1933-2874(10)00104-2

doi: 10.1016/j.jacl.2010.03.005

Journal of Clinical Lipidology
Volume 4, Issue 3 , Pages 152-155 , May 2010

Article Tools

* Image Usage & Resolution